Histogenics Corp. (NASDAQ:HSGX) major shareholder Split Rock Partners Ii, Lp bought 276,801 shares of the company’s stock in a transaction on Thursday, September 29th. The shares were acquired at an average price of $2.25 per share, for a total transaction of $622,802.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Histogenics Corp. (NASDAQ:HSGX) opened at 3.19 on Wednesday. The company has a 50 day moving average of $3.22 and a 200 day moving average of $2.34. Histogenics Corp. has a 12 month low of $1.39 and a 12 month high of $4.97. The stock’s market capitalization is $42.33 million.
Histogenics Corp. (NASDAQ:HSGX) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.01. During the same period last year, the firm posted ($0.58) earnings per share. On average, equities analysts predict that Histogenics Corp. will post ($2.11) EPS for the current year.
A hedge fund recently raised its stake in Histogenics Corp. stock. Sabby Management LLC increased its stake in Histogenics Corp. (NASDAQ:HSGX) by 28.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 150,630 shares of the company’s stock after buying an additional 32,965 shares during the period. Sabby Management LLC owned approximately 1.14% of Histogenics Corp. worth $345,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 38.63% of the company’s stock.
Several research analysts have issued reports on HSGX shares. BTIG Research upgraded shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 target price on the stock in a report on Thursday, August 11th. Zacks Investment Research upgraded shares of Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a report on Friday, August 26th. Needham & Company LLC raised their price target on shares of Histogenics Corp. from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, September 19th. Finally, William Blair cut shares of Histogenics Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Histogenics Corp. currently has an average rating of “Buy” and a consensus price target of $7.65.
About Histogenics Corp.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.